References
[1] Milson I. Compliance and the pill. In: Medical Products Agency, ed.
Contraceptive methods. The Norwegian Medicines Control Authority (Hrsg.).
1994: 113-122.
[2] Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4(3):191-215.
[3] Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States:
1982-1995. Fam Plann Perspect 1998; 30(1):4-10, 46.
[4] Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130(7):545-553.
[5] Gärtner R, Haen E. Endokrinpharmakologie. In: Forth W, Henschler D, Rummel W, eds. Allgemeine und spezielle Pharmakologie und Toxikologie.
München, Jena: Urban & Fischer. 2001: 671-737.
[6] Endokrines System. In: Knabe J, Höltje HD, eds. Lehrbuch der
pharmazeutischen Chemie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. 1991: 523-595.
[7] Hormonelles System. In: Mutschler E, Geisslinger G, Kroemer HK, Schäfer- Korting M, eds. Mutschler Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH
Stuttgart. 2001: 365-453.
[8] Kawata M. Subcellular steroid/nuclear receptor dynamics. Arch Histol Cytol 2001; 64(4):353-368.
[9] Lee SJ, McEwen BS. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 2001; 41:569- 591.
[10] Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones.
Eur J Endocrinol 2003; 148(3):281-292.
[11] Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors.
Trends Endocrinol Metab 2001; 12(4):152-156.
[12] Govind AP, Thampan RV. Membrane associated estrogen receptors and related proteins: localization at the plasma membrane and the endoplasmic reticulum. Mol Cell Biochem 2003; 253(1-2):233-240.
[13] McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001; 91(6):2785-2801.
[14] Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986; 15(2):213-218.
[15] Labrie F. Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol (Paris) 2003; 64(2):95-107.
[16] Jones KP. Estrogens and progestins: what to use and how to use it. Clin Obstet Gynecol 1992; 35(4):871-883.
[17] Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002; 346(5):340-352.
[18] McEwen BS, Alves SE. Estrogen actions in the central nervous system.
Endocr Rev 1999; 20(3):279-307.
[19] Haynes MP, Russell KS, Bender JR. Molecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol 2000; 7(5):500-508.
[20] Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24(2):152-182.
[21] Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;
231(4742):1150-1154.
[22] Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93(12):5925-5930.
[23] Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors.
Crit Rev Biochem Mol Biol 2002; 37(1):1-28.
[24] Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20(3):358-417.
[25] Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
Endocrinology 1999; 140(12):5566-5578.
[26] Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S et al. Comparison of the ligand binding specificity and transcript tissue
distribution of estrogen receptors alpha and beta. Endocrinology 1997;
138(3):863-870.
[27] Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82(12):4258-4265.
[28] Sarrel PM, Lufkin EG, Oursler MJ, Keefe D. Estrogen actions in arteries, bone and brain. Sci Med 1994;44-53.
[29] Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype:
potential role in the cell- and promoter-specific actions of estrogens and anti- estrogens. FEBS Lett 1997; 410(1):87-90.
[30] Ruggiero RJ, Likis FE. Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwifery Womens Health 2002; 47(3):130-138.
[31] Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.
Proc Natl Acad Sci U S A 1999; 96(16):8867-8872.
[32] Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW.
Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002; 57:339-355.
[33] Kong EH, Pike AC, Hubbard RE. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 2003; 31(Pt 1):56-59.
[34] Savouret JF, Muchardt C, Quesne M, Mantel A, Dee The H, Milgrom E.
Regulation of the progesterone receptor functions. Ann N Y Acad Sci 1998;
839:138-142.
[35] Speroff L. Role of progesterone in normal breast physiology. J Reprod Med 2002; 44(2 Suppl):172-179.
[36] Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev 1990;
11(2):386-398.
[37] Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002;
17(9):2307-2314.
[38] Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345(25):1787-1793.
[39] WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives:
results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349(9060):1202-1209.
[40] Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y et al. Risk of Arterial Thrombosis in Relation to Oral
Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33(5):1202-1208.
[41] Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284(1):72-78.
[42] Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F et al.
A comparison of the risks of venous thromboembolic disease in association
with different combined oral contraceptives. Br J Clin Pharmacol 2000;
49(6):580-590.
[43] Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321(7270):1190- 1195.
[44] Farmer RD, Lawrenson R. Utilization patterns of oral contraceptives in UK general practice. Contraception 1996; 53(4):211-215.
[45] Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos- Holzmann I, Bruppacher R. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Contraception 1998; 57(1):29-37.
[46] Soules MR, Bremner WJ. The menopause and climacteric: endocrinologic basis and associated symptomatology. J Am Geriatr Soc 1982; 30(9):547-561.
[47] Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998; 217(1):6- 16.
[48] Ososki AL, Kennelly EJ. Phytoestrogens: a review of the present state of research. Phytother Res 2003; 17(8):845-869.
[49] Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003; 10(1):65-72.
[50] Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;
346(26):2025-2032.
[51] Davidson NE, Helzlsouer KJ. Good news about oral contraceptives. N Engl J Med 2002; 346(26):2078-2079.
[52] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017):1713-1727.
[53] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54(3 Suppl):1S- 106S.
[54] Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000; 87(4):591-594.
[55] Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A et al.
Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002; 102(3):262-265.
[56] Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001; 95(6):370-374.
[57] Vessey MP, Painter R. Endometrial and ovarian cancer and oral
contraceptives--findings in a large cohort study. Br J Cancer 1995; 71(6):1340- 1342.
[58] Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I.
Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10(4):277-284.
[59] La Vecchia C, Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev 1999; 8(4):297-304.
[60] The Cancer and Steroid Hormone Study Group. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;
316(11):650-655.
[61] Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer.
Obstet Gynecol 1993; 82(6):931-935.
[62] The Cancer and Steroid Hormone Study Group. Combination oral
contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987; 257(6):796-800.
[63] Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305(12):672-677.
[64] Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous
thromboembolism. A case-control study. Contraception 1998; 57(5):291-301.
[65] Sartwell PE, Stolley PD. Oral contraceptives and vascular disease. Epidemiol Rev 1982; 4:95-109.
[66] Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE.
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133(1):32-37.
[67] Salonen JT. Oral contraceptives, smoking and risk of myocardial infarction in young women. A longitudinal population study in eastern Finland. Acta Med Scand 1982; 212(3):141-144.
[68] Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19:55-72.
[69] Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288(7):872-881.
[70] Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;
133(12):933-941.
[71] Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med 2001; 135(1):1-8.
[72] The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;
19(1):61-109.
[73] Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:
principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3):321-333.
[74] The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;
291(14):1701-1712.
[75] Manson JE, Hsia J, Johnson K, Rossouw JE, Assaf AR, Lasser NL et al.
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349(6):523-534.
[76] Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;
289(20):2673-2684.
[77] Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al.
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289(24):3243-3253.
[78] Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ et al. Estrogen plus progestin and colorectal cancer in
postmenopausal women. N Engl J Med 2004; 350(10):991-1004.
[79] Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK et al.
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289(20):2651-2662.
[80] Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE et al. Effect of estrogen plus progestin on global cognitive function in
postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289(20):2663-2672.
[81] Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE et al.
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348(19):1839-1854.
[82] Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and
Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;
280(7):605-613.
[83] Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al.
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;
288(1):49-57.
[84] Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W et al.
Noncardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1):58-66.
[85] Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR et al.
Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349(6):535-545.
[86] Beral V, Million Women Study Collaborators. Breast cancer and hormone- replacement therapy in the Million Women Study. Lancet 2003;
362(9382):419-427.
[87] Beral V, Banks E, Reeves G. Long term-effects of hormone replacement therapy. Lancet 2002; 390(9337):942-944.
[88] Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137(4):273-284.
[89] Neves-e-Castro M, Samsioe G, Doren M, O Skouby S. Results from WHI and HERS II--implications for women and the prescriber of HRT. Maturitas 2002;
42(4):255-258.
[90] Ottesen B, Pedersen AT. Physiological effects of ovarian hormones: clinical aspects and compliance. Eur Heart J 1996; 17(Suppl D):20-26.
[91] Nimtz-Köster R. Die große Hormon-Blamage. Spiegel [30], 140-143. 23-7- 2001.
Ref Type: Magazine Article
[92] Lilo Berg. Hormontherapie erneut im Test: Studie soll Brustkrebsrisiko für Deutschland ermitteln. Berliner Zeitung . 30-7-2002.
Ref Type: Newspaper
[93] GCP Study Group. The German Cardiovascular Prevention Study (GCP):
design and methods. GCP Study Group. Eur Heart J 1988; 9(10):1058-1066.
[94] Melchert HU, Görsch B, Hoffmeister H. Nichtstationäre
Arzneimittelanwendung und subjektive Arzneimittelverträglichkeit in der
bundesdeutschen Wohnbevölkerung der 25- bis 69jährigen: zur Epidemiologie des Arzneimittelkonsums und der unerwünschten Arzneimittelwirkungen;
Ergebnisse der Erhebung des ersten Nationalen Untersuchungs-Surveys 1984-1986. RKI-Schriften; 1995, 1 ed. München: MMV Medizin Verlag. 1995.
[95] Hoffmeister H, Hüttner H, Stolzenberg H, Lopez H, Winkler J. Sozialer Status und Gesundheit: Nationaler Gesundheits-Surveys 1984-1986. BGA-Schriften;
2/92 ed. München: MMV Medizin Verlag. 1992.
[96] Die Gesundheit der Deutschen: Ein Ost-West-Vergleich. RKI-Heft 7 ed. Berlin:
Robert Koch-Institut. 1995.
[97] Die Gesundheit der Deutschen (Band 2): Zusammenhänge zwischen
Gesundheit und Lebensstil, Umwelt und soziodemografischen Faktoren-Eine Auswertung von Surveydaten. Berlin: Robert Koch-Institut. 1996.
[98] Schwerpunktheft: Bundes-Gesundheitssurvey 1998. Das Gesundheitswesen 61[Sonderheft 2], S55-S222. 1999.
Ref Type: Journal (Full)
[99] Guidelines for ATC classification and DDD assignment. 4th ed. Oslo: WHO Collaborating Centre for Drug Statistical Methodology. 2001.
[100] Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy:
estimates from a nationally representative cohort study. Am J Epidemiol 1997;
145(6):536-545.
[101] Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF- 36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473- 483.
[102] Keller CH, Wolfram G. Fettstoffwechsel;Lipidsenker. In: Forth W, Henschler D, Rummel W, eds. Allgemeine und spezielle Pharmakologie und Toxikologie.
München, Jena: Urban & Fischer. 2001: 637-647.
[103] Expert Panel on Detection Evaluation and Treatment of High Blood
Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
[104] Strom BL. What is Pharmacoepidemiology? In: Strom BL, ed.
Pharrmacoepidemiology. John Wiley & Sons. 2000.
[105] Hartzeman AG. Pharmacoepidemiology: an introduction. Third ed. Harvey Whitney Books Company. 1998.
[106] Lewis MA. The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect.
Hum Reprod Update 1999; 5(6):707-720.
[107] Spitzer WO. The aftermath of a pill scare: regression to reassurance. Hum Reprod Update 1999; 5(6):736-745.
[108] Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995; 6(3):227-231.
[109] Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 2004; 143(10):971-978.
[110] Mueller JE, Döring A, Heier M, Löwel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. Maturitas 2002;
43(2):95-104.
[111] Heinemann K, Moehner S, Lewis M, Assmann A, Garbe E, Heinemann LA.
Trends of OC use 1980-1999 in a German cohort of women. Zentralbl Gynakol 2002; 124(2):128-131.
[112] Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women.
Contraception 1999; 59(5):277-286.
[113] Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 1997; 12(11):2347-2357.
[114] Heinemann LA. The changing scene--an unnecessary pill crisis. Hum Reprod Update 1999; 5(6):746-755.
[115] Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders:
an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312(7023):83-88.
[116] Melchert HU, Knopf H. Daten der Nationalen Untersuchungssurveys zum Verbrauch oraler Kontrazeptiva (OC) in West- und Ostdeutschland. In: Bärbel- Maria Bellach (Hrsg.), ed. Die Gesundheit der Deutschen (Band 2):
Zusammenhänge zwischen Gesundheit und Lebensstil, Umwelt und soziodemografischen Faktoren-Eine Auswertung von Surveydaten. Berlin:
Robert-Koch Institut. 1996: 133-148.
[117] Toulemon L, Leridon H. Contraceptive practices and trends in France. Fam Plann Perspect 1999; 30(3):114-120.
[118] Yusuf F, Siedlecky S. Contraceptive use in Australia: evidence from the 1995 National Health Survey. Aust N Z J Obstet Gynaecol 1999; 39(1):58-62.
[119] Wilkins K, Johansen H, Beaudet MP, Neutel CI. Oral contraceptive use. Health Rep 2000; 11(4):25-37.
[120] Ringa V, Ledesert B, Gueguen R, Schiele F, Breart G. Determinants of hormonal replacement therapy in recently postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1992; 45(3):193-200.
[121] Topo P, Klaukka T, Hemminki E, Uutela A. Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women. J Epidemiol Community Health 1991; 45(4):277-280.
[122] Townsend J. Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract 1998; 48(427):955-958.
[123] Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone replacement therapy: a population-based study of Swedish
women. The Women's Health in Lund Area (WHILA) Study. Menopause 2000;
7(4):273-281.
[124] Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance. Obstet Gynecol 1997; 90(2):269-277.
[125] Schaad MA, Bonjour JP, Rizzoli R. Evaluation of hormone replacement therapy use by the sales figures. Maturitas 2000; 34(2):185-191.
[126] Bakken K, Eggen AE, Lund E. Hormone replacement therapy in Norwegian women, 1996-1997. Maturitas 2001; 40(2):131-141.
[127] MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy:
prevalence, compliance and the 'healthy women' notion. Climacteric 1998;
1(1):42-49.
[128] Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE. The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994.
Menopause 2002; 9(4):264-272.
[129] Fotherby K, Caldwell AD. New progestogens in oral contraception.
Contraception 1994; 49(1):1-32.
[130] Poindexter A. The emerging use of the 20-microg oral contraceptive. Fertil Steril 2001; 75(3):457-465.
[131] Droegemueller W, Katta LR, Bright TG, Bowes WA Jr. Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol 1989; 161(5):1407-1411.
[132] Schilling LH, Bolding OT, Chenault CB, Chong AP, Fleury F, Forrest K et al.
Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial. Am J Obstet Gynecol 1989; 160(5 Pt 2):1264-1268.
[133] Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus
triphasic oral contraceptives for contraception. Contraception 2002; 65(5):321- 324.
[134] Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2003;(2):CD002032.
[135] The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275(5):370-375.
[136] Ettinger B, Woods NF, Barrett-Connor E, Pressman A. The North American Menopause Society 1998 menopause survey: Part II. Counseling about hormone replacement therapy: association with socioeconomic status and access to medical care. Ann Intern Med 2000; 7(3):143-148.
[137] Marks NF, Shinberg DS. Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998; 148(6):581-593.
[138] Sogaard AJ, Tollan A, Berntsen GK, Fonnebo V, Magnus JH. Hormone replacement therapy: knowledge, attitudes, self-reported use - and sales figures in Nordic women. Maturitas 2000; 35(3):201-214.
[139] Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-
controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971; 22(9):609-623.
[140] Mukherjea, Mukherjee P, Biswas R. Long-term contraception with Depo- Provera: a clinical evaluation. Int J Fertil 1980; 25(2):122-126.
[141] Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 1998;
58(6):345-349.
[142] Guillebaud J. Combined oral contraception. In: Glasier A, Gebbie A, eds.
Handbook of family planning. London: Churchill Livingstone. 2000: 29-76.
[143] Le MG, Laveissiere MN, Pelissier C. Factors associated with weight gain in women using oral contraceptives: results of a French 2001 opinion poll survey conducted on 1665 women. Gynecol Obstet Fertil 2003; 31(3):230-239.
[144] Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995; 52(4):215-219.
[145] Gupta S. Weight gain on the combined pill--is it real? Hum Reprod Update 2000; 6(5):427-431.
[146] Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2003;(2):CD003987.
[147] Lloyd T, Lin HM, Matthews AE, Bentley CM, Legro RS. Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol 2002;
100(2):235-239.
[148] Owen-Smith V, Hannaford PC, Warskyj M, Ferry S, Kay CR. Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal College of General Practitioners' Oral
Contraception Study in the UK. J Epidemiol Community Health 1998;
52(7):420-424.
[149] Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study.
Stroke 1994; 25(5):935-942.
[150] Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD,
Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral
contraceptives. Eur J Contracept Reprod Health Care 2000; 5(4):265-274.
[151] Royal College of General Practitioners' Oral Contraception Study. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet 1981; 1(8219):541-546.
[152] Shah S, Harris TJ, Cook DG. Differences in hormone replacement therapy use by social class, region and psychological symptoms. BJOG 2001; 108(3):269- 275.
[153] Knopf H, Melchert HU. Bundes-Gesundheitssurvey: Arzneimittelgebrauch- Konsumverhalten in Deutschland. Robert-Koch Institut, Berlin. 2003.
[154] Johansson SE, Sundquist J. Change in lifestyle factors and their influence on health status and all-cause mortality. Int J Epidemiol 1999; 28(6):1073-1080.
[155] Toobert DJ, Strycker LA, Glasgow RE, Barrera M, Bagdade JD. Enhancing support for health behavior change among women at risk for heart disease:
the Mediterranean Lifestyle Trial. Health Educ Res 2002; 17(5):574-585.
[156] WHO. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 2nd. 2000. Geneva, World Health Organization.
Ref Type: Pamphlet
[157] ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin.
The use of hormonal contraception in women with coexisting medical
conditions. Number 18, July 2000. Int J Gynaecol Obstet 2001; 75(1):93-106.
[158] Genazzani AR, Nicolucci A, Campagnoli C, Crosignani P, Nappi C, Serra GB et al. Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users. Maturitas 2002; 42(4):267-280.
[159] Blumel JE, Castelo-Branco C, Roncagliolo ME, Guanes PP, Lavin P. Do women using hormone replacement treatment have less pre-existing cardiovascular risk. Maturitas 2001; 38(3):315-319.
[160] Masse PG, Roberge AG. Long-term effect of low-dose combined steroid contraceptives on body iron status. Contraception 1992; 46(3):243-252.
[161] Task Force for Epidemiological Research on Reproductive Health. Effects of contraceptives on hemoglobin and ferritin. Contraception 1998; 58(5):262-273.
[162] Mooij PN, Thomas CM, Doesburg WH, Eskes TK. The effects of oral contraceptives and multivitamin supplementation on serum ferritin and
hematological parameters. Int J Clin Pharmacol Ther Toxicol 1992; 30(2):57- 62.
[163] Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75(5):898-915.
[164] Wilson DH, Taylor AW, MacLennan AH. Health status of hormone
replacement therapy users and non-users as determined by the SF-36 quality- of-life dimension. Climacteric 1998; 1(1):50-54.
[165] Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;
9(3):156-161.
[166] Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997; 104(10):1191-1195.
[167] Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause 2003; 10(1):29-36.
[168] Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a
placebo-controlled randomized trial. Obstet Gynecol 2000; 96(3):359-365.
[169] Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92(6):982-988.
[170] Spitzer WO. Bias versus causality: interpreting recent evidence of oral contraceptive studies. Am J Obstet Gynecol 1998; 179(3(Pt 2)):S43-S50.
[171] Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose
metabolism in a national sample of women in the united states. Am J Obstet Gynecol 2000; 183(2):389-395.
[172] Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD et al. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Diabetes Care 2002; 25(6):1027-1032.
[173] Smith CP, Tarn AC, Thomas JM, Overkamp D, Corakci A, Savage MO et al.
Between and within subject variation of the first phase insulin response to intravenous glucose. Diabetologia 1988; 31(2):123-125.
[174] Simon D, Senan C, Garnier P, Saint-Paul M, Garat E, Thibult N et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy
population: the Telecom study. Am J Obstet Gynecol 1990; 163(1 Pt 2):382- 387.
[175] Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B et al.
Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 1992;
35(10):967-972.
[176] Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA,
Spiegelman D et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997; 20(3):330-335.
[177] Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo Study.
Diabetes Care 1997; 20(4):645-649.
[178] Andersson B, Mattsson LA, Hahn L, Marin P, Lapidus L, Holm G et al.
Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;
82(2):638-643.
[179] Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE, NHANES III.
Hormone replacement therapy and its relationship to lipid and glucose
metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III).
Diabetes Care 2002; 25(10):1675-1680.
[180] Triusu RJ, Cowie CC, Harris MI. Hormone replacement therapy and glucose metabolism. Obstet Gynecol 2000; 96(5 Pt 1):665-670.
[181] Zhang Y, Howard BV, Cowan LD, Yeh J, Schaefer CF, Wild RA et al. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study.
Diabetes Care 2002; 25(3):500-504.
[182] Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V et al.
Glycemic effects of postmenopausal hormone therapy: the Heart and
Estrogen/progestin Replacement Study. A randomized, double-blind, placebo- controlled trial. Ann Intern Med 2003; 138(1):1-9.
[183] Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C et al.
Effect of oestrogen plus progestin on the incidence of diabetes in
postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47(7):1175-1187.
[184] Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998; 21(10):1589-1595.
[185] Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA 1977;
237(23):2499-2503.
[186] Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G et al. Prospective study of oral contraceptives and hypertension among
women in the United States. Circulation 1996; 94(3):483-489.
[187] Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997; 15(10):1063-1068.
[188] Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low- dose oral contraceptives and 24-hour ambulatory blood pressure. Int J
Gynaecol Obstet 1997; 59(3):237-243.
[189] Hussain SF. Progestogen-only pills and high blood pressure: is there an association?; A literature review. Contraception 2004; 69(2):89-97.
[190] Kuroski de Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res 1999; 41(3):524-531.
[191] Petitti DB. Combination Estrogen–Progestin Oral Contraceptives. N Engl J Med 2003; 349(15):1443-1450.
[192] The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273(3):199-208.
[193] Sumino H, Ichikawa S, Kumakura H, Takayama Y, Kanda T, Sakamaki T et al.
Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens Res 2003; 26(5):369-376.
[194] Hayward CS, Samaras K, Campbell L, Kelly RP. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 2001; 14(7 Pt 1):699-703.
[195] Mills PJ, Farag NH, Matthews S, Nelesen RA, Berry CC, Dimsdale JE.
Hormone replacement therapy does not affect 24-h ambulatory blood pressure in healthy non-smoking postmenopausal women. Blood Press Monit 2003;
8(2):57-61.
[196] Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004; 49(3):189-203.
[197] Mercuro G, Zoncu S, Piano D, Pilia I, Lao A, Melis GB et al. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998; 11(8 Pt 1):909-913.
[198] Cacciatore B, Paakkari I, Hasselblatt R, Nieminen MS, Toivonen J, Tikkanen MI et al. Randomized comparison between orally and transdermally
administered hormone replacement therapy regimens of long-term effects on
24-hour ambulatory blood pressure in postmenopausal women. Am J Obstet Gynecol 2001; 184(5):904-909.
[199] Scuteri A, Bos AJ, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001; 135(4):229-238.
[200] Sorensen MB, Rasmussen V, Jensen G, Ottesen B. Temporal changes in clinic and ambulatory blood pressure during cyclic post-menopausal hormone replacement therapy. J Hypertens 2001; 18(10):1387-1391.
[201] Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception 1997; 55(4):219-224.
[202] Connelly PW, Stachenko S, MacLean DR, Petrasovits A, Little JA. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
Can J Cardiol 1999; 15(4):419-427.
[203] Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, Marz W.
Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and
levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism.
Contraception 2004; 69(2):105-113.
[204] Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001; 24(6):443-456.
[205] Lobo RA, Skinner JB, Lippman JS, Cirillo SJ. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65(6):1100-1109.
[206] Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;
98(1):83-90.
[207] Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH et al.
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283(14):1845-1852.
[208] Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV et al. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study. Menopause 2003; 10(6):550-558.
[209] Ossewaarde ME, Dallinga-Thie GM, Bots ML, van der Schouw YT, Rabelink TJ, Grobbee DE et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest 2003; 33(5):376-382.
[210] Kuller LH. Hormone replacement therapy and risk of cardiovascular disease:
implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 2003; 23(1):11-16.
[211] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a
randomised placebo-controlled trial. Lancet 2002; 360(9326):7-22.
[212] Primatesta P, Falaschetti E, Poulter NR. Influence of hormone replacement therapy on C-reactive protein: population-based data. J Cardiovasc Risk 2003;
10(1):57-60.
[213] Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J.
Hormone replacement therapy: estrogen and progestin effects on plasma C- reactive protein concentrations. Am J Obstet Gynecol 2002; 186(5):969-977.
[214] Koh KK, Horne MK 3rd, Csako G, Waclawiw MA, Cannon RO 3rd. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in
postmenopausal women. Am J Cardiol 1999; 83(3):466-469.
[215] Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346(13):967-974.
[216] Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;
109(9):1056-1062.
[217] Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345(17):1243-1249.
[218] Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343(8):522-529.
[219] Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104(4):499-503.
[220] Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002; 5(4):317-325.
[221] Krebs in Deutschland: Häufigkeiten und Trends. 4. Überarbeitete, akualisierte Ausgabe ed. Saarbrücken: Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. 2004.
[222] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51
epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350(9084):1047-1059.
[223] Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
JAMA 2000; 283(4):485-491.
[224] Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287(6):734-741.
[225] Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000; 53(4):367-375.
[226] Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285(11):1460-1465.
[227] Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P et al.
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288(3):334-341.
[228] Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004; 15(1):100-105.
[229] Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290(13):1739-1748.
[230] Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000; 152(3):233-241.
[231] Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer M. A quantitative assessment of oral contraceptive use and risk of ovarian cancer.
Obstet Gynecol 1992; 80(4):708-714.
[232] Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus.
Contraception 1991; 43(6):557-579.
[233] Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995; 85(5pt1):793-801.
[234] Walker GR, Schlesselman JJ, Ness RB. Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 2000;
186(1):8-14.
[235] Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al.
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4):235- 240.
[236] Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2001; 189(1):280-294.
[237] Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol 2001;
44(1):62-72.
[238] Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001; 19(4):295-303.
[239] Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2000; 27(4):705-721.
[240] Kremser E, Mitchell GM. Treatment of primary dysmenorrhea with a combined type oral contraceptive--a double blind study. J Am Coll Health A 1971;
19(3):195-199.
[241] Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001;
4:CD002120.
[242] Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60(1):75-79.
[243] Brown S, Vessey M, Stratton I. The influence of method of contraception and cigarette smoking on menstrual patterns. Br J Obstet Gynaecol 1988;
95(9):905-910.
[244] Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron
supplementation. Ann Hematol 1998; 77(1-2):13-19.
[245] Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status.
Contraception 1992; 46(4):327-334.
[246] Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate- ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96(6):913-920.
[247] Rivera R, Almonte H, Arreola M, Lopez F, Monarrez G, Navarro C et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 1983; 27(3):311-327.
[248] Spinillo A, Gorini G, Piazzi G, Baltaro F, Monaco A, Zara F. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 1996; 54(3):163-168.
[249] Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144(6):630-635.
[250] Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. A word of caution about protection. JAMA 1985; 253(15):2246-2250.
[251] Lemay A, Langley RG. The use of low dose oral contraceptives for the management of acne. Skin Therapy Lett 2002; 7(10):1-5.
[252] Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis 2000; 66(4):281-286.
[253] van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995; 103(4):241-251.
[254] Sobbrio GA, Granata A, D'Arrigo F, Arena D, Panacea A, Trimarchi F et al.
Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Eur Fertil 1990; 21(3):139-141.
[255] Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188(5):1158-1160.
[256] Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne.
Contraception 1999; 60(5):255-262.
[257] Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A et al. Effects on acne of two oral contraceptives containing
desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996;
41(4):423-429.
[258] Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL.
Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89(4):615-622.
[259] Olson WH, Lippman JS, Robisch DM. The duration of response to
norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med 1998; 43(6):286-290.
[260] Martinez ME, Grodstein F, Giovannucci E, Colditz GA, Speizer FE, Hennekens C et al. A prospective study of reproductive factors, oral
contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997; 6(1):1-5.
[261] Fernandez E, La Vecchia C, Franceschi S, Braga C, Talamini R, Negri E et al.
Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;
9(3):295-300.
[262] Franceschi S, La Vecchia C. Oral contraceptives and colorectal tumors. A review of epidemiologic studies. Contraception 1998; 58(6):335-343.
[263] Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF Jr.
Reproductive factors, oral contraceptive use, and risk of colorectal cancer.
Epidemiology 1997; 8(1):75-79.
[264] Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis
Cooperative Research Group. Arch Intern Med 1991; 151(10):1971-1976.
[265] Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 1997; 176(5):1017-1025.
[266] Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC. Oral contraceptives and bone mineral density: A population-based study. Am J Obstet Gynecol 2001; 182(2):265-269.
[267] Lloyd T, Taylor DS, Lin HM, Matthews AE, Eggli DF, Legro RS. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril 2000; 74(4):734-738.
[268] Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002; 65(6):407-410.
[269] Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000;
61(2):77-82.
[270] Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 2001; 108(12):1214-1221.
[271] Cobb KL, Kelsey JL, Sidney S, Ettinger B, Lewis CE. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults. Osteoporos Int 2002; 13(11):893-900.